Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper.
Stern, Simon Chaudhuri, Satarupa Drayson, Mark Henshaw, Sarah Karunanithi, Kamaraj Willis, Fenella
Stern, Simon
Chaudhuri, Satarupa
Drayson, Mark
Henshaw, Sarah
Karunanithi, Kamaraj
Willis, Fenella
Abstract
This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed
MIDER Authors
Citations
Altmetric:
Date
2023-05-18
Type
Article
Subject
Haematology
Collections
Citation
Stern S, Chaudhuri S, Drayson M, Henshaw S, Karunanithi K, Willis F; Haemato-Oncology Task Force of the British Society for Haematology and the UK Myeloma Forum. Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper. Br J Haematol. 2023 Aug;202(4):734-744. doi: 10.1111/bjh.18866. Epub 2023 May 18. PMID: 37587091.
Journal / Source Title
British Journal of Haematology
DOI
10.1111/bjh.18866
PMID
37587091
Publisher
Wiley
Publisher’s URL
https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.18866